Are you Dr. Swaby?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 80 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111Phone+1 214-728-6900Fax+1 215-214-1425
Summary
- Dr. Ramona Swaby, MD is an oncologist in Philadelphia, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1999 - 2002
University of MarylandResidency, Internal Medicine, 1996 - 1999
University of Maryland School of MedicineClass of 1996
Certifications & Licensure
PA State Medical License 1999 - 2012
Clinical Trials
- Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer Start of enrollment: 2006 Aug 01
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Start of enrollment: 2007 Nov 02
- Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy Start of enrollment: 2008 Apr 01
Publications & Presentations
PubMed
- 56 citationsComparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, Tricia Bal, Ezra E.W. Cohen
Modern Pathology. 2021-03-01 - 9 citationsPembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head ...Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara
The Lancet. Oncology. 2024-05-01 - 100 citationsPembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Kevin J Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara
Journal of Clinical Oncology. 2023-02-01
Press Mentions
Kathy D Miller, MDJuly 7th, 2018
